Rain Therapeutics Inc (RAIN)

Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Data as of 2021-08-02 09:29:43 -0400
Market Cap440.936 Million Shares Outstanding26.483 Million Avg 30-day Volume92.253 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.91 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.0 52-week High/Low23.9 / 14.08 Next Earnings Date2021-08-25 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding RAIN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RAIN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

587 Thousand total shares from 6 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF I GP LLC

BIOTECHNOLOGY VALUE FUND II LP

BVF II GP LLC

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF GP HOLDINGS LLC

BVF INC/IL

LAMPERT MARK N

  • Director
  • 10% Owner
  • SEE REMARKSSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
7,962,851 2021-07-01 7

BERGER FRANKLIN M

  • Director
24,000 2021-05-14 2

WOLFF STEFANI

  • Director
24,000 2021-05-14 1

CABATUAN NELSON SEE REMARKS

  • Officer
6,000 2021-05-12 1

VELLANKI AVANISH PRESIDENT AND CEO

  • Officer
  • Director
2,511,442 2021-04-27 1

DOEBELE ROBERT EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
467,937 2021-04-27 1

RADOVICH PETER

  • Director
8,796 2021-04-27 1

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

EDELMAN JOSEPH

  • 10% Owner
2,537,019 2021-04-27 1

CORMORANT ASSET MANAGEMENT, LP

CHEN BIHUA

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

CORMORANT PRIVATE HEALTHCARE FUND III LP

CORMORANT PRIVATE HEALTHCARE FUND II, LP

  • Director
  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2021-04-27 1

DAVIS AARON I.

MVA INVESTORS, LLC

  • Director
  • 10% Owner
4,277,215 2021-04-23 1

BOXER CAPITAL, LLC

BOXER ASSET MANAGEMENT INC.

LEWIS JOSEPH

  • Director
  • 10% Owner
4,277,215 2021-04-23 1

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

BVF PARTNERS L P/IL - Director - > 10% Owner SEE REMARKS

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-07-06 19:34:13 -0400 2021-07-06 P 16,980 $15.25 a 149,480 direct 2.2039 8.8154 15.2066 4 0.0 1

BVF PARTNERS L P/IL - Director - > 10% Owner SEE REMARKS

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-07-06 19:34:13 -0400 2021-07-06 P 146,116 $15.25 a 1,259,873 direct 2.2039 8.8154 15.2066 4 0.0 1

BVF PARTNERS L P/IL - Director - > 10% Owner SEE REMARKS

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-07-06 19:34:13 -0400 2021-07-06 P 106,627 $15.25 a 917,803 direct 2.2039 8.8154 15.2066 4 0.0 1

BVF PARTNERS L P/IL - Director - > 10% Owner SEE REMARKS

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-07-06 19:34:13 -0400 2021-07-01 P 172,457 $15.65 a 1,113,757 direct 2.2039 8.8154 15.2066 4 0.0 1

BVF PARTNERS L P/IL - Director - > 10% Owner SEE REMARKS

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-07-06 19:34:13 -0400 2021-07-01 P 124,804 $15.65 a 811,176 direct 2.2039 8.8154 15.2066 4 0.0 1

BVF PARTNERS L P/IL - Director - > 10% Owner SEE REMARKS

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-07-06 19:34:13 -0400 2021-07-01 P 20,018 $15.65 a 132,500 direct 2.2039 8.8154 15.2066 4 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
RAIN THERAPEUTICS INC RAIN 2021-08-02 22:15:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 21:45:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 21:15:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 20:45:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 20:15:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 19:45:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 19:15:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 18:45:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 18:15:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 17:45:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 17:15:03 UTC -2.0373 2.0973 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 16:45:03 UTC -2.0389 2.1189 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 16:15:03 UTC -2.0389 2.1189 3000
RAIN THERAPEUTICS INC RAIN 2021-08-02 15:45:03 UTC -2.0389 2.1189 2000
RAIN THERAPEUTICS INC RAIN 2021-08-02 15:15:03 UTC -2.0389 2.1189 2000
RAIN THERAPEUTICS INC RAIN 2021-08-02 14:45:03 UTC -2.0389 2.1189 2000
RAIN THERAPEUTICS INC RAIN 2021-08-02 14:15:03 UTC -2.0389 2.1189 2000
RAIN THERAPEUTICS INC RAIN 2021-08-02 13:45:03 UTC -2.0389 2.1189 2000
RAIN THERAPEUTICS INC RAIN 2021-08-02 13:15:04 UTC -2.0389 2.1189 2000
RAIN THERAPEUTICS INC RAIN 2021-08-02 12:45:03 UTC -2.0389 2.1189 2000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments